Seung-Whan Lee, M.D., Ph.D.
Quick facts
Marketed products
- low-intensity statin plus ezetimibe · Cardiovascular
A combination therapy that reduces LDL cholesterol through dual inhibition of cholesterol synthesis (statin) and intestinal cholesterol absorption (ezetimibe).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: